INBX Stock Inhibrx Biosciences (INBX, $76.27) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 30, 2026

GET DAILY SIGNALS

Get AI intraday signals

INBX - Inhibrx Biosciences Inc.

MACD signal

View

Odds of UP Trend

Price: $76.27

Daily change: +$3.71 (+5.11%)

Daily volume: 291.7K

Capitalization: $1.1B

Industry: Biotechnology

This is a Bullish indicator signaling INBX's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 39 similar cases where INBX's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

INBX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for INBX turned positive on January 30, 2026. Looking at past instances where INBX's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 30, 2026. You may want to consider a long position or call options on INBX as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

INBX moved above its 50-day moving average on February 02, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where INBX advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for INBX crossed bearishly below the 50-day moving average on January 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INBX broke above its upper Bollinger Band on February 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INBX entered a downward trend on January 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.557) is normal, around the industry mean (27.519). P/E Ratio (0.198) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (909.091) is also within normal values, averaging (331.843).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.